SCHEMBL3019397

SCHEMBL3019397

COc1cc(Cc2csc(N3CCN(S(=O)(=O)c4cccc(Cl)c4)CC3)n2)cc(OC)c1OC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 2/20 0.45
LMNA P02545 2/20 0.45
THRB P10828 1/20 0.45
RECQL P46063 2/20 0.44
MAPT P10636 1/20 0.43
HSD17B10 Q99714 1/20 0.43
ALDH1A1 P00352 4/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
TSHR P16473 2/20 0.41
POLB P06746 1/20 0.41
HTT P42858 1/20 0.41
GBA1 P04062 2/20 0.41
MAPK1 P28482 1/20 0.41
HTR7 P34969 1/20 0.40
GFER P55789 1/20 0.40
HSD11B1 P28845 1/20 0.40
CHRM4 P08173 1/20 0.40
LPAR2 Q9HBW0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3015084 0.91 TSHR (0.48) USP2LMNARECQLMAPTHSD17B10
SCHEMBL3014079 0.91 ALDH1A1 (0.41) USP2LMNATHRBRECQLMAPT
SCHEMBL3017960 0.90 MAPT (0.45) USP2LMNARECQLMAPTHSD17B10
SCHEMBL3016767 0.90 USP2 (0.43) USP2RECQLMAPTHSD17B10ALDH1A1
SCHEMBL3007926 0.90 MEN1 (0.53) USP2LMNARECQLMAPTHSD17B10
SCHEMBL3018680 0.89 MAPT (0.49) USP2LMNARECQLMAPTHSD17B10
SCHEMBL3012681 0.89 SMN1; SMN2 (0.46) USP2LMNATHRBRECQLMAPT
SCHEMBL3015934 0.89 MAPT (0.45) USP2LMNARECQLMAPTHSD17B10
SCHEMBL3016067 0.88 ALDH1A1 (0.51) USP2LMNARECQLMAPTHSD17B10
SCHEMBL3018982 0.87 TSHR (0.51) USP2LMNARECQLMAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA USP2 1831/4885LMNA 80/4885THRB 2628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.